Advertisement

PharmacoEconomics & Outcomes News

, Volume 844, Issue 1, pp 30–30 | Cite as

Pegaspargase preferred option in acute lymphoblastic leukaemia

Clinical study
  • 1 Downloads

Reference

  1. Hu X, et al. The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis. Health Economics Review : 29 Dec 2019. Available from: URL: https://doi.org/10.1186/s13561-019-0257-3

Copyright information

© Springer International Publishing AG 2020

Personalised recommendations